AC Immune
Gautam Maitra is an experienced professional in regulatory affairs with a significant tenure at AC Immune SA since August 2007, where responsibilities include managing filings for two phase I clinical trials in Europe and engaging in extensive negotiations with health authorities. Gautam has also been a member of the Parenteral Drug Association (PDA) since 2007 and served as a CMC manager at Novartis from 1995 to 2002, further contributing to a robust career in the pharmaceutical industry.
This person is not in any teams
AC Immune
3 followers
AC Immune SA is clinical-stage biopharmaceutical company that aims to become a global leader in precision medicine for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen™ and Morphomer™, fuel its broad and diversified pipeline of first- and best-in-class assets, which currently features nine therapeutic and three diagnostic candidates, six of which are currently in clinical trials. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies including Genentech, a member of the Roche Group, Eli Lilly and Company, and Janssen Pharmaceuticals, Inc., resulting in substantial non-dilutive funding to advance its proprietary programs and >$3 billion in potential milestone payments.